NTBL

Notable Labs, Ltd.

1.49 USD
+0.03 (+2.05%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Notable Labs, Ltd. stock is up 26.27% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 February’s closed higher than January.

About Notable Labs, Ltd.

Vascular Biogenics Ltd. develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer.